Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2011-06-28
2011-06-28
Noakes, Suzanne M (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007100
Reexamination Certificate
active
07968284
ABSTRACT:
The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.
REFERENCES:
patent: 5284931 (1994-02-01), Springer et al.
patent: 5288854 (1994-02-01), Diamond et al.
patent: 5395929 (1995-03-01), Corbi et al.
patent: 5460945 (1995-10-01), Springer et al.
patent: 5475091 (1995-12-01), Springer et al.
patent: 5489533 (1996-02-01), Springer et al.
patent: 5512660 (1996-04-01), Springer et al.
patent: 5514555 (1996-05-01), Springer et al.
patent: 5565550 (1996-10-01), Springer et al.
patent: 5599676 (1997-02-01), Vonderheide et al.
patent: 5612216 (1997-03-01), Springer et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5629162 (1997-05-01), deFougerolles et al.
patent: 5686265 (1997-11-01), Corbi et al.
patent: 5739032 (1998-04-01), Springer et al.
patent: 5747035 (1998-05-01), Presta et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5843712 (1998-12-01), Levine
patent: 5849896 (1998-12-01), Springer et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5877295 (1999-03-01), Diamond et al.
patent: 5891841 (1999-04-01), deFougerolles et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 5948758 (1999-09-01), Springer et al.
patent: 6030947 (2000-02-01), Corbi et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 6096871 (2000-08-01), Presta et al.
patent: 6121022 (2000-09-01), Presta et al.
patent: 6121428 (2000-09-01), Blank et al.
patent: 6358510 (2002-03-01), Springer et al.
patent: 6413963 (2002-07-01), Kahn et al.
patent: 6436403 (2002-08-01), Springer et al.
patent: 6511664 (2003-01-01), Springer et al.
patent: 6582698 (2003-03-01), Mizutani et al.
patent: 6572856 (2003-06-01), Taylor et al.
patent: 6683158 (2004-01-01), Springer et al.
patent: 6777191 (2004-08-01), Springer et al.
patent: 6797270 (2004-09-01), Springer et al.
patent: 2001/0031260 (2001-10-01), Lee et al.
patent: 2003/0054440 (2003-03-01), Mayo et al.
patent: 440351 (1991-08-01), None
patent: WO 94/04188 (1994-03-01), None
“National PBM Drug Monograph Efalizumab”, www.vapbm.org, (Feb. 2004),1-25.
Bajt, et al., “Characterization of a Gain of Function Mutation of Integrin Alpha IIb beta 3 (platelet glycoprotein IIb-IIIx)”,J. Biol. Chem, 267, (1992),22211-22216.
Bost KL, Pascual DW,Antibodies Against a Peptide Sequence within the HIV Envelope Protein Crossreacts with Human Interleukin-2, Immunol. Invest., 17(6-7):577-586, 1988.
Bullard, et al., “A Polygenic Mouse Model of Psoriasiforn Skin Disease in CD18-deficient Mice”,PNAS, 93, (1996),2116-2121.
Champe, et al., “Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen I Recognize Three Discrete Epitopes in the Inserted Domain of CAlla”,J. Biol. Chem., 270 (3), (1995),1388-1394.
Dransfield, et al., “Divalent Cation Regulation of the Function of the Leukocyte Integrin LFA-1”,J. Cell Biol., 116, (1992),219-226.
Dransfield, et al., “Interaction of Leukocyte Integrins with Ligand is Necessary but Not Sufficient for Function”,J. Cell. Biol., 116, (1992),1527-1535.
Huang, et al., “A Binding Interface on the I Domaine of Lymphocyte Function-associated Antigen-I (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule I (ICAM-1)”,J. Biol. Chem., 270, (1995),19008-19016.
Huang, et al., “Folding of the Beta-Propeller Domain of the Integrin AlphaL Subunit is Independent of the I Domain and Dependent on the Beta2 Subunit”,Proc. Natl. Acad.Sci. USA, 94(7), (1997),3162-3167.
Keizer, et al., “A Monoclonal Antibody (NKI-L16) Directed Against a Unique Epitope on the x-chain of Human Leukocyte Function Associated Antigen I . . . ”,J. Immunol., 140, (1988),1393.
Kooyk, et al., “Activation of LFA-1 Through the Ca2+-Dependent Epitope Stimulates Lymphocyte Adhesion”,J. Cell Biol., 112, (1991),345-354.
Landis, et al., “A Novel LFA-1 Activation Epitope Maps to the I Domain”,J. Cell Biol., 120 ,.(1993),1519-1527.
Landis, et al., “Involvement of the “I” Domain of the LFA-1 in Selective Binding to Ligands ICAM-1 and ICAM-3”,J. Cell. Biol., 126, (1994),529-537.
Larson, et al., “Primary Structure of the Leukocyte Function-associated Molecule 1xSubunit: An Integrin with an Embedded Domain Defining a Protein Superfamily”,J. Cell Biol., 108, (1989),703-712.
Lu, et al., “Locking in Alternate Conformations of the Integrin AlphaLbeta2 I Domain with Disulfide Bonds Reveals Functional Relationships Among Integrin Domains”,Proc. Natl. Acad. Sci. USA, 98(5), (2001),2393-2398.
Owens RJ, Young RJ, “The Genetic Engineering of Monoclonal Antibodies”,J. Immunol. Methods, 168(2), (1994),149-165.
Oxvig, et al., “Conformational Changes in Tertiary Structure Near the Ligand Binding Site of an Integrin I Domain”,PNAS, 96, (1999),2215-2200.
Qu, et al., “Crystal Structure of the I-Domain from the CD11a/CD18 (LFA-1, xb2) Integin”,PNAS, 92, (1995),10277-10281.
Salas, et al., “Transition from Rolling to Firm Adhesion is Regulated by the Conformation of the I Domain of the Integrin Lymphocyte Function-associated Antigen-1”,J. Biol. Chem, 277(52), (2002),50255-50262.
Lu Chafen
Shimaoka Motomu
Springer Timothy A.
Lee Jae W
Noakes Suzanne M
Rissman Hendricks & Oliverio LLP
The Center for Blood Research, Inc.
LandOfFree
Modified polypeptides stabilized in a desired conformation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified polypeptides stabilized in a desired conformation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified polypeptides stabilized in a desired conformation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672754